Key result
Genetically predicted lower CoQ10 levels and rs66554427 variant linked to higher risk of SAMS.
Why the study?
Do CoQ10-related genetic determinants increase the risk of statin-associated muscle symptoms?
Observational
Yes
Do CoQ10-related genetic determinants increase the risk of statin-associated muscle symptoms?
Answers are grounded in this paper and cite their sources.
Genetic variants predicting lower CoQ10 levels increase susceptibility to statin-associated muscle symptoms, supporting a causal role for impaired CoQ10 biosynthesis.
). Significant additive and multiplicative interactions between statin and rs66554427 were observed (P < 0.001). PRS analyses further demonstrated that genetically predicted lower CoQ10 levels were associated with a higher risk of SAMS. Using COQ7 protein levels as a proxy for CoQ10 biosynthesis, we identified statin-specific genetic susceptibility to SAMS and supported a causal role of impaired CoQ10 biosynthesis in SAMS.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) conducted an observational in Statin-Associated Muscle Symptoms (SAMS). Genetically predicted lower CoQ10 levels and statin use was evaluated on Statin-Associated Muscle Symptoms (SAMS) (p=<0.001). Genetically predicted lower CoQ10 levels and the rs66554427 variant were associated with a higher risk of statin-associated muscle symptoms.
Synapse has enriched 10 related papers. Consider them for comparative context: